Molecular Evolution of Antibody Cross-reactivity for Two Subtypes of Type A Botulinum Neurotoxin
Overview
Authors
Affiliations
Broadening antibody specificity without compromising affinity should facilitate detection and neutralization of toxin and viral subtypes. We used yeast display and a co-selection strategy to increase cross-reactivity of a single chain (sc) Fv antibody to botulinum neurotoxin type A (BoNT/A). Starting with a scFv that binds the BoNT/A1 subtype with high affinity (136 pM) and the BoNT/A2 subtype with low affinity (109 nM), we increased its affinity for BoNT/A2 1,250-fold, to 87 pM, while maintaining high-affinity binding to BoNT/A1 (115 pM). To find the molecular basis for improved cross-reactivity, we determined the X-ray co-crystal structures of wild-type and cross-reactive antibodies complexed to BoNT/A1 at resolutions up to 2.6 A, and measured the thermodynamic contribution of BoNT/A1 and A2 amino acids to wild-type and cross-reactive antibody binding. The results show how an antibody can be engineered to bind two different antigens despite structural differences in the antigen-antibody interface and may provide a general strategy for tuning antibody specificity and cross-reactivity.
Wang W, Bunyatov M, Lopez-Barbosa N, DeLisa M bioRxiv. 2025; .
PMID: 40027839 PMC: 11870402. DOI: 10.1101/2025.02.12.637914.
Selection of Candidate Monoclonal Antibodies for Therapy of Botulinum Toxin Type A Intoxications.
Zeninskaya N, Ryabko A, Marin M, Kombarova T, Shkuratova M, Rogozin M Toxins (Basel). 2024; 16(7).
PMID: 39057924 PMC: 11281656. DOI: 10.3390/toxins16070284.
Structural basis for antiepileptic drugs and botulinum neurotoxin recognition of SV2A.
Yamagata A, Ito K, Suzuki T, Dohmae N, Terada T, Shirouzu M Nat Commun. 2024; 15(1):3027.
PMID: 38637505 PMC: 11026379. DOI: 10.1038/s41467-024-47322-4.
Joensuu M, Syed P, Saber S, Lanoue V, Wallis T, Rae J EMBO J. 2023; 42(13):e112095.
PMID: 37226896 PMC: 10308369. DOI: 10.15252/embj.2022112095.
Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs.
Teixeira A, DAngelo S, Erasmus M, Leal-Lopes C, Ferrara F, Spector L MAbs. 2022; 14(1):2115200.
PMID: 36068722 PMC: 9467613. DOI: 10.1080/19420862.2022.2115200.